All In Biotech

Drug Trial Radar · NCT02872116

Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer

A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination With Oxaliplatin Plus Fluoropyrimidine Versus Oxaliplatin Plus Fluoropyrimidine in Subjects With Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Last checked: Nov 19, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,031 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,031

Actual

Start

Oct 12, 2016

Primary completion

May 27, 2020

Study completion Jun 6, 2024

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Ono Pharmaceutical Co., Ltd.
First posted
Aug 19, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to compare how long patients with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab or nivolumab and chemotherapy compared with patients receiving chemotherapy alone.

Conditions

  • Gastric Cancer
  • Gastroesophageal Junction Cancer
  • Esophageal Adenocarcinoma

Interventions

  • NivolumabDrug

    Specified dose on specified days

  • IpilimumabDrug

    Specified dose on specified days

  • OxaliplatinDrug

    Specified dose on specified days

  • CapecitabineDrug

    Specified dose on specified days

  • LeucovorinDrug

    Specified dose on specified days

  • FluorouracilDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) in Participants Treated With Nivolumab Plus Chemotherapy vs Chemotherapy With PD-L1 CPS ≥ 5Time frame: From the date of randomization up to the date of death, up to approximately 17 months
  2. Progression Free Survival (PFS) in Participants Treated With Nivolumab Plus Chemotherapy vs Chemotherapy With PD-L1 CPS ≥ 5Time frame: From randomization to the date of the first documented progressive disease (PD) per BICR or death due to any cause (up to approximately 10 months)

Locations

179 sites in 29 countries. Site status is shown where the registry gives one.

  • Local Institution - 0005

    Los Angeles, California

  • Local Institution - 0001

    San Francisco, California

  • Local Institution - 0066

    Aurora, Colorado

  • Local Institution - 0151

    Denver, Colorado

  • Local Institution - 0136

    Washington D.C., District of Columbia

  • Florida Cancer Specialists S.

    Fort Myers, Florida

  • Local Institution - 0147

    Miami, Florida

  • Florida Cancer Specialists

    St. Petersburg, Florida

  • Local Institution - 0179

    Marietta, Georgia

  • Local Institution - 0219

    Arlington Heights, Illinois

  • Local Institution - 0120

    Chicago, Illinois

  • Local Institution - 0021

    Baltimore, Maryland

  • Local Institution - 0002

    Boston, Massachusetts

  • Local Institution - 0135

    Boston, Massachusetts

  • Local Institution - 0003

    New York, New York

  • Local Institution - 0138

    Cleveland, Ohio

  • Local Institution - 0186

    Cleveland, Ohio

  • Local Institution - 0146

    Eugene, Oregon

  • Lehigh Valley Health Network

    Allentown, Pennsylvania

  • Local Institution - 0065

    Pittsburgh, Pennsylvania

  • Local Institution - 0104

    Nashville, Tennessee

  • Local Institution - 0140

    Bedford, Texas

  • Local Institution - 0143

    Dallas, Texas

  • Local Institution - 0213

    Dallas, Texas

  • Local Institution - 0004

    Houston, Texas

  • Texas Oncology-Plano East

    Plano, Texas

  • Local Institution - 0150

    Newport News, Virginia

  • Local Institution - 0027

    Córdoba, Argentina

  • Local Institution - 0184

    La Rioja, Argentina

  • Local Institution - 0183

    Viedma, Argentina

  • Local Institution - 0030

    Caba, Buenos Aires, Argentina

  • Local Institution - 0028

    Capital Federal, Buenos Aires, Argentina

  • Local Institution - 0029

    Capital Federal, Buenos Aires, Argentina

  • Local Institution - 0026

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Local Institution - 0202

    Blacktown, New South Wales, Australia

  • Local Institution - 0100

    Gosford, New South Wales, Australia

  • Local Institution - 0190

    Southport, Queensland, Australia

  • Local Institution - 0101

    Adelaide, South Australia, Australia

  • Local Institution - 0103

    Ballarat, Victoria, Australia

  • Local Institution - 0102

    Shepparton, Victoria, Australia

Showing 40 of 179 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.